Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-031 in Acute Ischemic Stroke
NCT06226805Phase 2Recruiting
- Sponsor
- Basking Biosciences
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of BB-031 in ischemic stroke, sponsored by Basking Biosciences. Started Jul 2024; status: recruiting.
02
Drugs
BB-031
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06226805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226805.